Literature DB >> 2393226

Preferred postoperative alignment after congenital esotropia surgery.

A R Caputo1, S Guo, R S Wagner, M V Picciano.   

Abstract

A total of 117 patients with congenital esotropia who underwent muscle surgery were included in our study and were followed for a minimum of three years. Only those patients who were orthotropic or were within +/- 10 prism diopters (PD) of orthotropia six months postoperatively were included. Of the 117 patients, 101 patients (86%) remained orthotropic or within +/- 10 PD of orthotropia three years postoperatively, but 13 patients (11%) developed consecutive exotropia (greater than 10 PD). Five years after surgery, 17 of 68 patients (25%) had consecutive exotropia (greater than 10 PD). Our study demonstrates that despite satisfactory postoperative alignment, there is a steady progression towards exotropic drift over long-term follow-up. Our study also suggests that a preferred alignment shortly after congenital esotropia surgery is within 10 PD of esotropia since all of the patients who had consecutive exotropia (greater than 10 PD) were either orthotropic or exotropic (less than or equal to 10 PD) six months after surgery.

Entities:  

Mesh:

Year:  1990        PMID: 2393226

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  3 in total

1.  [Dose-effect relation in revision surgery for consecutive strabismus divergens in adults].

Authors:  A Langmann; S Lindner; M Koch; W Wackernagel; R Hörantner
Journal:  Ophthalmologe       Date:  2005-09       Impact factor: 1.059

2.  Long-term surgical outcomes of patients with consecutive exotropia.

Authors:  Haeng-Jin Lee; Young Suk Yu; Seong-Joon Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-13       Impact factor: 3.117

3.  Is the incidence of infantile esotropia declining?: a population-based study from Olmsted County, Minnesota, 1965 to 1994.

Authors:  Curtis R Louwagie; Nancy N Diehl; Amy E Greenberg; Brian G Mohney
Journal:  Arch Ophthalmol       Date:  2009-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.